Jacobson AK
Cardiology Section (111C), Loma Linda VA Medical Center, Loma Linda, California.
J Thromb Thrombolysis. 1998 Jan;5 Suppl 1(3):25-28. doi: 10.1023/a:1013280702839.
The clinical use of oral anticoagulant therapy has been complicated by the necessity for frequent determinations of the prothrombin time (PT) to ensure safety and therapeutic efficacy. This requirement has often imposed a significant burden on both providers and patients. In 1985 a German patient, Heike Möller-Jung, initiated her own patient self-testing (PST) and patient self-management (PSM). Today there are over 15,000 patients in Germany managing their oral anticoagulant therapy with PSM options. Pilot PST and PSM programs are in place in many other countries. In the United States, two devices have recently been approved for PST. This method of monitoring has been shown to be as accurate as that of traditional central laboratory PT determinations, to improve the amount of time patients are within the therapeutic INR range, and to decrease the incidence of adverse events associated with anticoagulant therapy.
口服抗凝治疗的临床应用因需要频繁测定凝血酶原时间（PT）以确保安全和治疗效果而变得复杂。这一要求常常给医疗服务提供者和患者都带来了沉重负担。1985年，德国患者海克·默勒 - 荣格开始了自己的患者自我检测（PST）和患者自我管理（PSM）。如今，德国有超过15000名患者通过PSM选项管理他们的口服抗凝治疗。许多其他国家也在开展PST和PSM试点项目。在美国，最近有两种设备被批准用于PST。这种监测方法已被证明与传统的中心实验室PT测定一样准确，能增加患者处于治疗性国际标准化比值（INR）范围内的时间，并降低与抗凝治疗相关的不良事件发生率。
